RS52672B2 - Tretman reumatoidnih bolesti glukokortikoidom sa odloženim-oslobađanjem - Google Patents

Tretman reumatoidnih bolesti glukokortikoidom sa odloženim-oslobađanjem

Info

Publication number
RS52672B2
RS52672B2 RS20130069A RSP20130069A RS52672B2 RS 52672 B2 RS52672 B2 RS 52672B2 RS 20130069 A RS20130069 A RS 20130069A RS P20130069 A RSP20130069 A RS P20130069A RS 52672 B2 RS52672 B2 RS 52672B2
Authority
RS
Serbia
Prior art keywords
delayed
dosage form
release dosage
glucocorticoid
use according
Prior art date
Application number
RS20130069A
Other languages
English (en)
Inventor
Achim SCHÄFFLER
Original Assignee
Horizon Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38739340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS52672(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Horizon Pharma Ag filed Critical Horizon Pharma Ag
Publication of RS52672B publication Critical patent/RS52672B/sr
Publication of RS52672B2 publication Critical patent/RS52672B2/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Claims (11)

Patentni zahtevi
1. Glukokortikoid sadržan u doznom obliku sa odloženim-oslobađanjem za upotrebu u tretmanu pacijenta koji pati od znakova i simptoma koji leže u osnovi reumatske bolesti i/ili osteoartritisa, gde se pomenuti tretman daje jednom dnevno uveče tokom najmanje dve nedelje.
2. Glukokortikoid sadržan u doznom obliku sa odloženim-oslobađanjem za upotrebu u tretmanu pacijenta koji pati od jutarnje ukočenosti i bola koji leže u osnovi reumatske bolesti i/ili osteoartritisa, gde se pomenuti tretman daje jednom dnevno uveče tokom najmanje dve nedelje.
3. Glukokortikoid sadržan u doznom obliku sa odloženim-oslobađanjem za upotrebu prema bilo kom od zahteva 1 do 2, gde se pomenuti tretman daje jednom dnevno uveče tokom najmanje četiri nedelje, tokom najmanje osam nedelja, ili tokom najmanje dvanaest nedelja.
4. Glukokortikoid sadržan u doznom obliku sa odloženim-oslobađanjem za upotrebu prema bilo kom od prethodnih zahteva, gde je reumatska bolest reumatoidni artritis, ankilozni spondilitis, i/ili reumatična polimialgija.
5. Glukokortikoid sadržan u doznom obliku sa odloženim-oslobađanjem za upotrebu prema bilo kom od prethodnih zahteva, gde je pomenuti pacijent tretiran, ili nije prethodno tretiran, sa NSAID, DMARD, TNFα inhibitorom , analgetskim agensom ili njihovim kombinacijama.
6. Glukokortikoid sadržan u doznom obliku sa odloženim-oslobađanjem za upotrebu prema bilo kom od prethodnih zahteva, gde tretman dalje obuhvata davanje pomenutom pacijentu efektivne količine NSAID, DMARD, TNFα inhibitora, analgetskog agensa, ili njihovih kombinacija.
7. Glukokortikoid sadržan u doznom obliku sa odloženim-oslobađanjem za upotrebu prema bilo kom od prethodnih zahteva, gde pomenuti tretman sadrži davanje pomenutom pacijentu efektivne količine glukokortikoida sadržanog u doznom obliku za odloženooslobađanje, gde se pomenuti tretman daje jednom dnevno uveče tokom najmanje dve nedelje.
8. Glukokortikoid sadržan u doznom obliku sa odloženim-oslobađanjem za upotrebu prema bilo kom od prethodnih zahteva, gde dozni oblik za odloženo-oslobađanje ima vreme zaostajanja od 2 časa do 6 časova, poželjno od 3 časa do 5 časova nakon davanja.
9. Glukokortikoid sadržan u doznom obliku sa odloženim-oslobađanjem za upotrebu prema bilo kom od prethodnih zahteva, gde je dozni oblik za odloženo-oslobađanje tableta.
10. Glukokortikoid sadržan u doznom obliku sa odloženim-oslobađanjem za upotrebu prema bilo kom od prethodnih zahteva, gde je glukokortikoid kortizon, hidrokortizon, prednison, prednisolon, metilprednisolon, budesonid, deksametazon, fludrokortizon, fluokortolon, kloprednol, deflazakort, triamcinolon, poželjno prednison i njihove odgovarajuće soli i estre.
11. Glukokortikoid sadržan u doznom obliku sa odloženim-oslobađanjem za upotrebu prema bilo kom od prethodnih zahteva, gde je pomenuti dozni oblik sa odloženim-oslobađanjem efektivan pri nižoj dozi glukokortikoida u poređenju sa davanjem pomenutog glukokortikoida u doznom obliku za trenutno oslobađanje.
RS20130069A 2006-08-03 2007-08-03 Tretman reumatoidnih bolesti glukokortikoidom sa odloženim-oslobađanjem RS52672B2 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83509306P 2006-08-03 2006-08-03
EP07801510.4A EP2049123B2 (en) 2006-08-03 2007-08-03 Delayed-release glucocorticoid treatment of rheumatoid disease
PCT/EP2007/006894 WO2008015018A1 (en) 2006-08-03 2007-08-03 Delayed-release glucocorticoid treatment of rheumatoid disease

Publications (2)

Publication Number Publication Date
RS52672B RS52672B (sr) 2013-06-28
RS52672B2 true RS52672B2 (sr) 2018-03-30

Family

ID=38739340

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20130069A RS52672B2 (sr) 2006-08-03 2007-08-03 Tretman reumatoidnih bolesti glukokortikoidom sa odloženim-oslobađanjem

Country Status (26)

Country Link
US (5) US20080076743A1 (sr)
EP (1) EP2049123B2 (sr)
JP (1) JP2009545546A (sr)
KR (1) KR101430089B1 (sr)
CN (1) CN101466385B (sr)
AU (1) AU2007280636B2 (sr)
BR (1) BRPI0717052A2 (sr)
CA (1) CA2655682A1 (sr)
DK (1) DK2049123T4 (sr)
EA (1) EA015304B1 (sr)
ES (1) ES2400446T5 (sr)
HR (1) HRP20130148T4 (sr)
IL (1) IL195155A (sr)
MA (1) MA30665B1 (sr)
MX (1) MX2009001248A (sr)
MY (1) MY149863A (sr)
NO (1) NO20090958L (sr)
PL (1) PL2049123T5 (sr)
PT (1) PT2049123E (sr)
RS (1) RS52672B2 (sr)
SG (2) SG10201503411QA (sr)
SI (2) SI2049123T2 (sr)
TN (1) TNSN08385A1 (sr)
UA (1) UA96457C2 (sr)
WO (1) WO2008015018A1 (sr)
ZA (1) ZA200809858B (sr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA015304B1 (ru) 2006-08-03 2011-06-30 Нитек Фарма Аг Лечение ревматоидного заболевания глюкокортикоидами с отсроченным высвобождением
EP2391369A1 (en) * 2009-01-26 2011-12-07 Nitec Pharma AG Delayed-release glucocorticoid treatment of asthma
NZ582836A (en) * 2009-01-30 2011-06-30 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
PT2563450T (pt) * 2010-04-28 2017-08-28 Kimberly Clark Co Dispositivo para entrega de medicação para a artrite reumatóide
JP6239517B2 (ja) * 2011-10-10 2017-11-29 メディミューン リミテッド 関節リウマチの治療法
GB201202433D0 (en) * 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
US9012432B2 (en) * 2013-03-08 2015-04-21 Levolta Pharmaceuticals, Inc. Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis

Family Cites Families (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3048526A (en) 1958-08-04 1962-08-07 Wander Company Medicinal tablet
GB972128A (en) 1960-01-21 1964-10-07 Wellcome Found Pellets for supplying biologically active substances to ruminants and the manufacture of such pellets
US3125491A (en) 1962-04-06 1964-03-17 Chew able hematinic vitamin tablet
FR1603314A (en) 1965-02-23 1971-04-05 Pharmaceutical tablets - having a core and a matrix material
US3870790A (en) 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
FR2100858B1 (sr) 1970-07-03 1975-06-06 Daiichi Seiyaku Co
DE2445971A1 (de) 1974-09-24 1976-04-08 Schering Ag Arzneimittelwirkstofftraeger ii
US4797288A (en) 1984-10-05 1989-01-10 Warner-Lambert Company Novel drug delivery system
GB8518301D0 (en) 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
US5519057A (en) 1986-11-14 1996-05-21 Johnson & Johnson--Merck Pharmaceuticals Co. Ibuprofen-containing medicament
IT1201136B (it) 1987-01-13 1989-01-27 Resa Farma Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
GB8705083D0 (en) 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
GB8820353D0 (en) 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5047246A (en) 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
IT1230576B (it) 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
US4966770A (en) 1989-07-26 1990-10-30 Himedics, Inc. Prednisone microencapsulated granules
DE3930770A1 (de) 1989-09-14 1991-03-28 Wolfgang F Dr Schoener Implantierbare katheter aus medizinisch vertraeglichem elastischen kunststoff
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
JP2558396B2 (ja) 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
JP2521848B2 (ja) 1990-07-02 1996-08-07 ベーリンガー マンハイム ゲーエムベーハー 成形され、圧縮された徐放性単位投薬形態の調製法およびこうして得られた圧縮単位投薬形態
ES2056470T3 (es) 1990-07-02 1994-10-01 Boehringer Mannheim Gmbh Proceso para la obtencion de dosis unitarias de liberacion retardada, prensadas en molde, y las dosis unitarias correspondientes.
IE61651B1 (en) 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
US5310578A (en) 1990-09-17 1994-05-10 Merck Patent Gesellschaft Deposition of cosmetically functional material onto pigments and fillers
US5316772A (en) 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
JPH06504276A (ja) 1991-01-03 1994-05-19 グラクソ、カナダ、インコーポレーテッド 固形製剤の製造法
DE4100920A1 (de) * 1991-01-15 1992-07-16 Degussa Wirkstoffzubereitung zur oralen verabreichung an wiederkaeuer
DE69222006T2 (de) 1991-10-30 1998-01-22 Glaxo Group Ltd Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten
WO1993019741A1 (en) 1992-03-31 1993-10-14 Benzon Pharma A/S A pharmaceutical formulation
GB9215908D0 (en) 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
WO1994007470A1 (en) 1992-09-30 1994-04-14 Pfizer Inc. Article containing a core and a coating having a non constant thickness
WO1994008589A1 (en) 1992-10-09 1994-04-28 The Board Of Trustees Of The Leland Stanford Junior University Treatment of systemic lupus erythematosus with dehydroepiandrosterone
TW272942B (sr) 1993-02-10 1996-03-21 Takeda Pharm Industry Co Ltd
DK66493D0 (da) 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
IL110376A (en) 1993-08-02 1998-08-16 Bristol Myers Squibb Co Pharmaceutical compositions containing ifetroban salts and methods for the preparation thereof
DE4332394A1 (de) 1993-09-23 1995-03-30 Falk Pharma Gmbh Budesonid-Pellets mit kontrolliertem Freigabeprofil und Verfahren zu ihrer Herstellung
US5482718A (en) 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US5702723A (en) 1994-08-02 1997-12-30 Griffin; David Multi-stage delivery system for ingestible medications or nutrients
US5811388A (en) 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
US5709880A (en) 1995-07-10 1998-01-20 Buckman Laboratories International, Inc. Method of making tabletized ionene polymers
IT1276031B1 (it) 1995-10-31 1997-10-24 Angelini Ricerche Spa Composizione farmaceutica per il trattamento delle malattie autoimmuni
JP3220373B2 (ja) 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
AU1751997A (en) 1996-01-30 1997-08-22 Advanced Polymer Systems Inc. Targeted delivery of drugs to the lower gastrointestinal tract
IT1282576B1 (it) 1996-02-06 1998-03-31 Jagotec Ag Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili
HRP970493A2 (en) 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
DE69730982T2 (de) 1996-10-28 2005-09-01 General Mills, Inc., Minneapolis Einbettung und einkapselung von teilchen zur kontrollierten abgabe
US5792476A (en) * 1996-12-19 1998-08-11 Abigo Medical Ab Sustained release glucocorticoid pharmaceutical composition
US5788987A (en) 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
SK180499A3 (en) 1997-07-01 2001-08-06 Pfizer Sertraline salts and sustained-release dosage forms of sertraline
US6013280A (en) 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres
ATE238774T1 (de) 1997-10-09 2003-05-15 Dexcel Pharma Technologies Ltd Darreichungsform zur verzögerten, vollständigen wirkstoffabgabe im verdauungstrakt
US7201923B1 (en) 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
DE69917618T2 (de) 1998-04-03 2005-06-23 Egalet A/S Zusammensetzung mit kontrollierter wirkstoff-freisetzung
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
ATE433318T1 (de) 1999-02-10 2009-06-15 Pfizer Prod Inc Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6677326B2 (en) 1999-03-15 2004-01-13 Arakis, Ltd. Corticosteroid formulation comprising less than 2.5 mg prednisolone for once daily administration
GB9905898D0 (en) * 1999-03-15 1999-05-05 Darwin Discovery Ltd Controlled-dose formulation
US6245352B1 (en) 1999-04-27 2001-06-12 Eli Lilly And Company Pharmaceutical formulation
JP2001010950A (ja) 1999-06-29 2001-01-16 Taiyo Yakuhin Kogyo Kk 安定で良好な薬物放出を有する医薬組成物
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
EP1074249A1 (en) 1999-07-27 2001-02-07 Jagotec Ag A pharmaceutical tablet system for releasing at least one active substance during a release period subsequent to a no-release period
US6428809B1 (en) 1999-08-18 2002-08-06 Microdose Technologies, Inc. Metering and packaging of controlled release medication
AR026148A1 (es) 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
DE10012555A1 (de) 2000-03-15 2001-09-20 Merck Patent Gmbh Glucocorticoide in einer Modified Release-Formulierung
DE10014588A1 (de) 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
DE10015479A1 (de) 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
US20020028240A1 (en) 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
AU2001247887A1 (en) 2000-04-19 2001-11-07 Eurand America Inc. Dual mechanism timed release dosage forms for low dose drugs
DE10029201A1 (de) 2000-06-19 2001-12-20 Basf Ag Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6720005B1 (en) 2000-07-07 2004-04-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Coated, platform-generating tablet
US6620439B1 (en) 2000-10-03 2003-09-16 Atul M. Mehta Chrono delivery formulations and method of use thereof
US6589562B1 (en) 2000-10-25 2003-07-08 Salvona L.L.C. Multicomponent biodegradable bioadhesive controlled release system for oral care products
US6565873B1 (en) 2000-10-25 2003-05-20 Salvona Llc Biodegradable bioadhesive controlled release system of nano-particles for oral care products
US6887493B2 (en) 2000-10-25 2005-05-03 Adi Shefer Multi component controlled release system for oral care, food products, nutraceutical, and beverages
WO2002072033A2 (en) 2001-03-13 2002-09-19 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms containing glucocorticosteroid
CA2441007C (en) 2001-03-15 2009-06-09 Enteron Pharmaceuticals, Inc. Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
IN191028B (sr) 2001-05-17 2003-09-13 Sun Pharmaceutical Ind Ltd
US20030021841A1 (en) 2001-07-02 2003-01-30 Matharu Amol Singh Pharmaceutical composition
PL370793A1 (en) 2001-07-04 2005-05-30 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
US7163700B2 (en) 2001-07-31 2007-01-16 Capricorn Pharma, Inc. Amorphous drug beads
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
EP2957281A1 (en) 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
WO2003026626A2 (en) 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Modified release dosage forms
EP1443912B1 (en) 2001-10-12 2007-08-29 Elan Pharma International Limited Compositions having a combination of immediate release and controlled release characteristics
US20080145438A1 (en) 2001-12-20 2008-06-19 Beuford Arlie Bogue Micro- and nano-particulate drugs and methods of making thereof
EP1465596A1 (en) 2002-01-18 2004-10-13 Control Delivery Systems, Inc. Polymeric gel system for the controlled delivery of codrugs
US20030215513A1 (en) 2002-02-21 2003-11-20 Peter Fyhr Method for releasing nanosized particles of an active substance from a diffusion-controlled pharmaceutical composition for oral use
KR20040091135A (ko) 2002-03-14 2004-10-27 다이이찌 산토리 파마 가부시키가이샤 염산 필지카이니드 함유 정제(건식)
ATE343376T1 (de) 2002-03-20 2006-11-15 Elan Pharma Int Ltd Nanopartikelzusammensetzungen von angiogeneseinhibitoren
US7074426B2 (en) 2002-03-27 2006-07-11 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20040062778A1 (en) 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
NZ538842A (en) 2002-09-28 2008-03-28 Mcneil Ppc Inc Immediate release dosage form comprising a solid core of density 0.9 g/ml surrounded by a shell that is readily soluble to gastrointestinal fluids
US20080220074A1 (en) 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
US7704527B2 (en) 2002-10-25 2010-04-27 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
ATE514418T1 (de) 2002-11-12 2011-07-15 Elan Pharma Int Ltd Rasch zerfallende feste darreichungsformen mit nichtbröseliger konsistenz und pullulan
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
MXPA05011446A (es) 2003-04-24 2006-05-31 Jagotec Ag Tableta con liberacion retardada con geometria de nucleo definida.
ES2335008T3 (es) 2003-04-24 2010-03-18 Jagotec Ag Comprimido con nucleo coloreado.
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
US20060177507A1 (en) 2003-05-22 2006-08-10 Joaquina Faour Controlled release device containing lercanidipine
UY28326A1 (es) 2003-05-22 2004-06-30 Osmotica Argentina S A Dispositivo de ruptura de liberacion controlada con un pasaje preformado
JP2007001865A (ja) 2003-09-16 2007-01-11 Ltt Bio-Pharma Co Ltd 脂溶性薬物封入微粒子、その製造法およびそれを含有する製剤
US20050118267A1 (en) 2003-09-19 2005-06-02 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
DE102004035936A1 (de) 2004-07-23 2006-03-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform
DE102004043863A1 (de) 2004-09-10 2006-03-16 Nitec Pharma Ag Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum
WO2006027266A1 (en) 2004-09-10 2006-03-16 Nitec Pharma Ag Tablets with site time-controlled gastrointestinal release of active ingredient
GB0427455D0 (en) 2004-12-15 2005-01-19 Jagotec Ag Dosage forms
JP2008533157A (ja) 2005-03-14 2008-08-21 マサチューセッツ・インスティテュート・オブ・テクノロジー 疾患および障害の診断および処置のためのナノセル
US9149439B2 (en) 2005-03-21 2015-10-06 Sandoz Ag Multi-particulate, modified-release composition
US7884136B2 (en) 2005-06-27 2011-02-08 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
WO2007036952A2 (en) 2005-07-01 2007-04-05 Rubicon Research Pvt Ltd. Novel sustained release dosage form
UA91376C2 (ru) 2005-08-24 2010-07-26 Рубикон Рисеч Пвт Лтд. Рецептура с контролируемым высвобождением
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
US9125833B2 (en) 2005-11-02 2015-09-08 Relmada Therapeutics, Inc. Multimodal abuse resistant and extended release opioid formulations
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
CA2631757A1 (en) 2005-12-02 2007-06-07 Elan Pharma International Limited Novel mometasone compositions and methods of making and using the same
US20080213374A1 (en) 2006-07-10 2008-09-04 Elan Pharma International Limited Nanoparticulate sorafenib formulations
US20080014272A1 (en) 2006-07-11 2008-01-17 Phil Skolnick Compositions and Methods for Treatment of Chronic Pain Conditions
US20080026040A1 (en) 2006-07-31 2008-01-31 Isaac Farr Active agent-releasing dosage forms
EA015304B1 (ru) 2006-08-03 2011-06-30 Нитек Фарма Аг Лечение ревматоидного заболевания глюкокортикоидами с отсроченным высвобождением
EP2046284A1 (en) 2006-08-04 2009-04-15 Nastech Pharmaceutical Company Inc. Compositions for intranasal delivery of human insulin and uses thereof
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
WO2008025535A1 (en) 2006-08-30 2008-03-06 Jagotec Ag Controlled release oral dosage formulations comprising a core and one or more barrier layers
WO2008028193A2 (en) 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
JP2010502690A (ja) 2006-09-08 2010-01-28 フォーミックス エルティーディー． 有色または着色可能発泡性組成物
WO2008033351A2 (en) 2006-09-11 2008-03-20 Theraquest Biosciences, Inc. Multimodal abuse resistant and extended release formulations
AU2007320737B2 (en) 2006-11-14 2014-04-03 Celsus Therapeutics Plc Contact lens compositions
WO2008079963A2 (en) 2006-12-22 2008-07-03 Cambrex Charles City, Inc. Pharmaceutical compositions comprising ionic complexes of active pharmaceutical ingredients
WO2008085484A2 (en) 2006-12-28 2008-07-17 Jacobus Pharmaceutical Company, Inc. Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
GB2445539A (en) 2006-12-29 2008-07-16 Ardana Bioscience Ltd Bigel composition
WO2008094877A2 (en) 2007-01-30 2008-08-07 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
WO2008104996A2 (en) 2007-02-28 2008-09-04 Jubilant Organosys Limited Water dispersible pharmaceutical formulation and process for preparing the same
JP5550546B2 (ja) 2007-04-13 2014-07-16 ケムジェネックス・ファーマシューティカルズ・インコーポレイテッド 経口セファロタキシン剤形
US8877249B2 (en) 2007-04-13 2014-11-04 Dow Global Technologies Llc Granular material for dosage forms
WO2008140460A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
US20080286343A1 (en) 2007-05-16 2008-11-20 Dzenana Cengic Solid form
US20080311162A1 (en) 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
WO2008140459A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
SI2167033T1 (sl) 2007-05-30 2017-08-31 Veloxis Pharmaceuticals A/S Odmerna oblika, ki obsega takrolimus, za dajanje enkrat na dan
NZ580972A (en) 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
EP2008651A1 (en) 2007-06-26 2008-12-31 Drug Delivery Solutions Limited A bioerodible patch
RU2010109408A (ru) 2007-08-13 2011-09-20 Панацея Биотек Лимитед (In) Композиции с пролонгированным высвобождением, включающие микофенолят натрия, и их действия
EP2203056A1 (en) 2007-09-25 2010-07-07 Nirmal Mulye Controlled release pharmaceutical compositions
HRP20191104T1 (hr) 2007-09-25 2019-09-20 Solubest Ltd. Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu
AR068745A1 (es) 2007-10-08 2009-12-02 Panacea Biotec Ltd Una composicion en forma de dosificacion farmaceutica oral de unidad de alta dosis de micofenolato sodico, metodo para utilizar dicha composicion y sus usos
JP2011500553A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド ５−アミノサリチル酸またはその塩もしくは代謝産物の新規な結腸を標的とする調節放出性生体接着性製剤
US20090131386A1 (en) 2007-11-13 2009-05-21 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
US20110092449A1 (en) 2007-12-21 2011-04-21 Bradford James Duft Treatment of fibrotic conditions
AU2008343755A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides and peptides for the treatment ofabnormal or excessive scars
CA2710382A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of orthopedic conditions
BRPI0909030A2 (pt) 2008-03-05 2018-03-13 Panacea Biotec Ltd composições farmacêuticas de liberação modificada compreendendo micofenolato e processos para as mesmas.
WO2009142772A2 (en) 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
US8648119B2 (en) 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
WO2009152479A1 (en) 2008-06-12 2009-12-17 University Of Alabama Huntsville Compositions comprising nitric oxide or nitric oxide donors for the treatment of neurodegenerative diseases of trauma
GB2462022B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
EP2391369A1 (en) 2009-01-26 2011-12-07 Nitec Pharma AG Delayed-release glucocorticoid treatment of asthma
NZ582836A (en) 2009-01-30 2011-06-30 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage

Also Published As

Publication number Publication date
RS52672B (sr) 2013-06-28
JP2009545546A (ja) 2009-12-24
EP2049123A1 (en) 2009-04-22
IL195155A0 (en) 2009-09-22
US20120070499A1 (en) 2012-03-22
CA2655682A1 (en) 2008-02-07
CN101466385A (zh) 2009-06-24
EP2049123B1 (en) 2012-11-28
HRP20130148T1 (en) 2013-03-31
AU2007280636B2 (en) 2013-07-18
US20170281648A1 (en) 2017-10-05
AU2007280636A1 (en) 2008-02-07
PT2049123E (pt) 2013-03-06
SG10201503411QA (en) 2015-06-29
DK2049123T3 (da) 2013-03-04
NO20090958L (no) 2009-04-30
HK1130423A1 (en) 2009-12-31
SI2049123T1 (sl) 2013-04-30
US20080076743A1 (en) 2008-03-27
US20140065214A1 (en) 2014-03-06
MA30665B1 (fr) 2009-08-03
KR20090045149A (ko) 2009-05-07
BRPI0717052A2 (pt) 2013-10-15
US8920838B2 (en) 2014-12-30
ES2400446T3 (es) 2013-04-09
KR101430089B1 (ko) 2014-08-13
PL2049123T3 (pl) 2013-04-30
SG174026A1 (en) 2011-09-29
ZA200809858B (en) 2009-10-28
ES2400446T5 (es) 2017-03-13
EA200900259A1 (ru) 2009-06-30
SI2049123T2 (sl) 2016-10-28
EA015304B1 (ru) 2011-06-30
UA96457C2 (ru) 2011-11-10
IL195155A (en) 2016-05-31
EP2049123B2 (en) 2016-08-24
DK2049123T4 (en) 2016-11-28
US20150141388A1 (en) 2015-05-21
MX2009001248A (es) 2009-02-11
PL2049123T5 (pl) 2017-09-29
TNSN08385A1 (en) 2009-12-29
WO2008015018A1 (en) 2008-02-07
CN101466385B (zh) 2014-01-08
US9504699B2 (en) 2016-11-29
MY149863A (en) 2013-10-31
HRP20130148T4 (hr) 2016-10-07

Similar Documents

Publication Publication Date Title
RS52672B2 (sr) Tretman reumatoidnih bolesti glukokortikoidom sa odloženim-oslobađanjem
HRP20210348T1 (hr) Farmaceutski sastavi za terapiju zamjene glukokortikoida
HRP20230272T1 (hr) Postupci za liječenje cistične fibroze
WO2016062283A1 (zh) 抗发炎用药物在制备抑制癌症的医药组合物中的应用
HRP20231142T3 (hr) Kontrolirano oslobađanje 25-hidroksivitamina d
ATE477804T1 (de) Verfahren zur behandlung von entzündlichen erkrankungen des verdauungstrakts mit topisch wirksamen kortikosteroiden
IL320452A (en) Combination therapy for prostate cancer
JP2020516646A5 (sr)
JP2009545546A5 (sr)
IL294736A (en) Preparations including 15-hydroxy-eicosapentaenoic acid and methods of using them
JP2016505050A5 (sr)
EP2341900A1 (en) A medicinal product and treatment
CA2389025A1 (fr) Composition hormonale a base d'un progestatif et d'un oestrogene et son utilisation
JP2009510051A5 (sr)
AR075345A1 (es) Tratamiento con glucocorticoides de liberacion retardada de artritis reumatoidea que mejora signos y sintomas, muestra respuesta clinica total o completa y previene el dano a las articulaciones
CN105055516A (zh) 一组由糖皮质激素与丹参提取物组成的具有骨保护作用的抗炎新药
JP2021504370A5 (sr)
JP2021169472A5 (sr)
CN115835862A (zh) 治疗阿尔茨海默病的组合及其应用
Singh et al. Corticosteroids and their therapeutic applications in dentistry
Davari et al. Management of Lichen Planus in a Post Liver Transplant Patient with Lupus Erythematosus, and Ulcerative Colitis; A Case Report
CN120078784A (zh) 他汀类药物和糖皮质激素治疗类风湿性关节炎的联合治疗
CA2488066A1 (en) Treatment of spondylarthropathies
Reid et al. A single infusion of zoledronic acid 5 mg is significantly more effective than daily oral risedronate 5 mg in increasing bone mineral density of the lumbar spine, hip, femoral neck and trochanter in patients with glucocorticoid-induced osteoporosis
RU2627424C1 (ru) Фармацевтический препарат для лечения ревматологических заболеваний